Dosing and concentration
Confirm the exact molecule before discussing a dose. A fragment and full-length thymosin beta-4 do not share interchangeable instructions. A loading or maintenance cycle cannot be selected from the name TB-500 alone.
Concentration arithmetic is still useful for understanding a record. A documented 5 mg amount in a final volume of 2 mL equals 2.5 mg/mL. This calculation says nothing about whether the contents are full-length thymosin beta-4 or a fragment, or whether that preparation is suitable for human use.
Preparation and reconstitution
A lyophilised vial contains freeze-dried material. Before any human-use preparation is considered, the identity and intended use must be clear. Dissolving a research vial does not establish that it is an injectable medicine.
Bacteriostatic water contains a preservative. Its preservative does not resolve identity, remove endotoxin or prove that a particular TB-500 preparation is compatible with the liquid. The amount of water should come from formulation instructions, not a desired syringe marking.
For an appropriately prescribed preparation, the instructions should specify the exact peptide, diluent, volume, mixing method, final concentration and discard limit. Use clean preparation conditions and sterile single-use equipment. Do not pool materials, improvise a blend or add another solvent to make particles disappear.
Keep the preparation record attached to the batch. “Five milligrams in the vial” and “five milligrams administered” are very different statements. The final concentration is needed to understand any recorded volume.
Administration
Subcutaneous means beneath the skin, not into the injured structure. Injecting into a tendon, joint or near a nerve carries risks and is not established as a way to improve TB-500 targeting.
For any prescribed injectable medicine, site and device teaching should be specific to the preparation. Rotate appropriate sites, avoid damaged or infected skin and use new sterile equipment each time. A needle selected from a general peptide shopping list does not replace technique instruction.
Do not mistake less pain for permission to load an injury aggressively. Worsening redness, heat, swelling, fever, new weakness or an inability to bear weight requires assessment of the injury or a possible complication.
Routes and bioavailability
Oral delivery exposes peptides to digestion. A capsule may protect contents from one part of the digestive tract without proving that an intact active molecule reaches a distant tendon.
Some oral compounds act locally in the gut, where high blood exposure is unnecessary. That rationale must be demonstrated for the particular compound. It is not established simply by saying that oral TB-500 is poorly absorbed.
Injection bypasses initial digestion but does not establish better healing. Full-length thymosin beta-4 and the TB-500 fragment cannot share a route-conversion rule.
Half-life
A dependable half-life for the TB-500 fragment is not available. Do not substitute the value for full-length thymosin beta-4.
Storage
Use storage and after-mixing instructions belonging to the identified preparation. A generic 30-day refrigerated period is not established by the peptide name or by adding bacteriostatic water.
Keep unopened expiry, preparation date and first-puncture date separate. Protect material as directed and record significant heat exposure. Do not freeze or repeatedly thaw a solution without formulation-specific instructions.
Unexpected particles, a compromised seal or an uncertain preparation history cannot be corrected by appearance checks alone. Preservatives do not make every contaminated or unstable solution usable.
Contraindications and side effects
The limited human evidence for the fragment means uncommon and long-term adverse effects are poorly characterised. Injection-related infection and immune reactions are concerns independent of any proposed repair mechanism.
Active cancer or a history requiring oncology follow-up deserves specialist discussion before exposure to experimental compounds associated with cell movement and tissue signalling. This is a precaution based on the biology and uncertainty, not proof that TB-500 causes cancer.
Pregnancy, breastfeeding and children are not settings for self-directed use. A new lump, unexplained bleeding, fever or a deteriorating injury needs medical assessment. Do not use a peptide response as a substitute for diagnosing the original problem.
Tracking progress and everyday questions
Track the specific movement, load, range of motion and next-day response. Keep the diagnosis and rehabilitation milestones with the record. Photos may help document visible swelling, but they cannot show internal tendon strength.
Is TB-500 definitely full-length thymosin beta-4? No; the name is used inconsistently. Does it need a loading phase? A human healing benefit from a standard loading phase has not been demonstrated here. Should it be injected beside an injury? That is not an established targeting strategy.